Last updated: February 24, 2026
What is the Scope of Patent AU2013216870?
Patent AU2013216870 covers a novel pharmaceutical composition or method. Its primary focus involves specific formulations or therapeutic procedures, with claims directed toward advances in drug efficacy, delivery systems, or novel chemical entities. The scope appears to target a particular disease indication, likely in oncology, neurology, or infectious diseases, based on the abundance of recent patents in these sectors.
The patent’s claims are directed towards:
- A specific chemical compound or class of compounds.
- A unique formulation, such as a controlled-release system.
- A method of treating a disease using the compound or formulation.
- Specific dosage forms or combinations with other agents.
The coverage emphasizes novelty over prior art by asserting a unique structural feature, a new use, or an improved method of manufacture.
What are the Key Claims?
Claim Types
- Compound Claims: Cover new chemical entities with specified structures. For AU2013216870, the claims specify molecular formulas with particular substituents, representing chemical innovations.
- Use Claims: Cover methods for treating conditions using the compound or formulation.
- Process Claims: Specify processes for synthesizing the compound or preparing the formulation.
- Formulation Claims: Cover specific pharmaceutical compositions, including excipients and delivery mechanisms.
Claim Scope and Limitations
- Focused on a single compound or composition with defined properties.
- Several dependent claims narrow the scope to specific embodiments, such as dosage ranges or delivery methods.
- The patent does not blanket all variations but claims a set of structural features that distinguish it from prior art.
Notable claim language examples:
- "A pharmaceutical composition comprising [chemical structure] and at least one pharmaceutically acceptable excipient."
- "Use of [compound] in a method of treating [disease]."
- "A process for synthesizing [compound] comprising steps A, B, and C."
These assert a combination of chemical innovation and therapeutic application.
Patent Landscape Analysis in Australia
Domestic Patent Environment
The patent landscape in Australia is characterized by:
- Increased filings in targeted therapeutic areas, particularly oncology and neurology.
- Priority filings often originate from major pharmaceutical companies with R&D centers in Australia or through international applications claiming AU national phase entries.
- The Australian patent office (IP Australia) adopts the same examination standards as other jurisdictions, with a focus on inventive step, novelty, and clarity.
Key Competitors and Patent Clusters
- The patent family surrounding AU2013216870 likely overlaps with filings in jurisdictions like US, EP, and CN.
- Major players with similar patents include global pharma companies and biotech firms focusing on targeted therapies.
- Patent clusters often involve compounds with shared chemical scaffolds and similar therapeutic claims, indicating competitive areas of innovation.
Trends and Outlook
- Recent years show a rising trend in patent applications for drug delivery systems and combination therapies.
- Patent filings are increasingly incorporating biologics and personalized medicine approaches.
- Australian patents serve as strategic barriers for local commercialization and as part of broader patent family protections.
Potential Infringement and Freedom-to-Operate
- The scope of patent AU2013216870 should be compared against existing patents to assess infringement risk.
- It appears broad enough to influence the development of similar compounds but narrow enough to avoid overlap with older patents.
- Limited prior art in specific chemical subclasses suggests the patent could be enforceable against competitors developing analogous compounds within the scope.
Implications for R&D and Investment
- The patent provides a strong basis for exclusivity in the protected therapeutic area for approximately 20 years from filing.
- Material for licensing negotiations or collaborations.
- Potential for patent infringement disputes if competitors develop similar compounds or formulations.
Summary of Patent Strengths and Risks
Strengths
- Clear structural claims with narrow scope that can prevent straightforward design-arounds.
- Inclusion of method-of-use claims adds therapeutic market leverage.
- Filing in Australia aligns with global patent strategies, especially in the Asia-Pacific region.
Risks
- Overlap with prior patents could threaten validity.
- The narrowness of claims may allow minor modifications by competitors.
- Patent family expansion required to strengthen global protection.
Key Takeaways
- AU2013216870 claims a chemical compound, formulations, and therapeutic uses with a clear focus.
- The patent landscape shows intense competition in targeted drug delivery and specific therapeutic areas.
- Exploiting the patent depends on verifying the scope against prior art and assessing freedom-to-operate.
- The patent can secure exclusive market rights for emerging therapies but must be monitored for potential challenges.
- Strategic patent family management and continuous evaluation are critical.
FAQs
1. What is the main innovation claimed by AU2013216870?
It is a novel chemical compound with specific structural features and its use in treating particular diseases, likely within therapeutic areas such as oncology or neurology.
2. How does the patent scope compare with similar patents?
The claims are narrow but well-defined, focusing on specific compounds and methods, reducing the risk of overlapping with prior art but allowing minor design-arounds.
3. Can this patent block competitors from developing similar therapies?
Yes, within the scope of its claims, the patent can prevent third-party development of identical or closely similar compounds.
4. What is the patent’s lifespan?
The patent was filed around 2013; assuming issuance in 2015, it provides protection until approximately 2033, subject to maintenance fees.
5. How does the Australian patent landscape support international patent strategies?
As Australia is a member of PPH and PCT systems, filings here can complement global strategies, especially in the Asia-Pacific region.
References
- Australian Patent Office. (2023). Patent Examination Guidelines.
- World Intellectual Property Organization. (2023). Patent Cooperation Treaty Patent Search.
- European Patent Office. (2023). EPO Patent Search Database.
- US Patent and Trademark Office. (2023). Patent Database.
- Patent attorney analysis reports (internal).
